Abiopharma

🔍 AKKARAJU SRINIVAS (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Acquired 588,235 shares of Common Stock at $25.5 per share (Direct)
  Date: 2025-09-04 | Code: P | equity_swap_involved: 0 | shares_owned_after: 588,235.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: By Samsara BioCapital, L.P. | shares_owned_after: 5,674,916.00 | Footnotes: F2

Footnotes:

• F1: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opp LP"). Samsara Opportunity Fund GP, LLC ("Samsara Opp GP") is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. The Reporting Person has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
• F2: Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.